2021
Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States
Wang X, Zeidan AM, Wang R, Bewersdorf JP, Zhang C, Podoltsev NA, Huntington SF, Gore SD, Ma X. Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. Leukemia & Lymphoma 2021, 62: 2438-2447. PMID: 33899659, DOI: 10.1080/10428194.2021.1913142.Peer-Reviewed Original ResearchConceptsPopulation-based studyDNA methyltransferase inhibitorRARS patientsRefractory anemiaRing sideroblastsRed blood cell transfusion independenceEnd Results-Medicare databaseLower-risk myelodysplastic syndromesPopulation-based cohortMethyltransferase inhibitorRBC-TIMedian durationMedian survivalOlder patientsTransfusion independenceTreatment initiationMyelodysplastic syndromeClinical effectivenessBetter survivalLenalidomideTreatment groupsPatientsRS statusOlder adultsAnemia
2018
Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States
Ma X, Steensma DP, Scott BL, Kiselev P, Sugrue MM, Swern AS. Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States. BMJ Open 2018, 8: e019955. PMID: 30037860, PMCID: PMC6059277, DOI: 10.1136/bmjopen-2017-019955.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnemiaAzacitidineDatabases, FactualDecitabineElectronic Health RecordsEnzyme InhibitorsFemaleHematinicsHumansImmunologic FactorsIron Chelating AgentsLenalidomideMaleMiddle AgedMultivariate AnalysisMyelodysplastic SyndromesProportional Hazards ModelsRecurrenceRetrospective StudiesThalidomideTreatment OutcomeUnited StatesConceptsDisease-modifying therapiesErythropoiesis-stimulating agentsElectronic medical record databaseMyelodysplastic syndromeMedical record databasePatient characteristicsTreatment patternsGE Centricity Electronic Medical Records databaseRecord databaseLow baseline hemoglobin levelMultivariable Cox regression modelsLarge electronic medical record databaseBaseline hemoglobin levelAbsence of comorbiditiesFirst-line treatmentMajority of patientsSelection of patientsCox regression modelIron chelation therapyAgent azacitidineMore comorbiditiesHemoglobin levelsMale genderClinical trialsChelation therapy